KR20260080518A - 동종이계 세포 조성물 및 이의 사용 방법 - Google Patents

동종이계 세포 조성물 및 이의 사용 방법

Info

Publication number
KR20260080518A
KR20260080518A KR1020267016462A KR20267016462A KR20260080518A KR 20260080518 A KR20260080518 A KR 20260080518A KR 1020267016462 A KR1020267016462 A KR 1020267016462A KR 20267016462 A KR20267016462 A KR 20267016462A KR 20260080518 A KR20260080518 A KR 20260080518A
Authority
KR
South Korea
Prior art keywords
cells
cell
modified
csr
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267016462A
Other languages
English (en)
Korean (ko)
Inventor
에릭 엠 오스터택
데본 쉐들록
Original Assignee
포세이다 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포세이다 테라퓨틱스, 인크. filed Critical 포세이다 테라퓨틱스, 인크.
Publication of KR20260080518A publication Critical patent/KR20260080518A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020267016462A 2018-09-05 2019-09-05 동종이계 세포 조성물 및 이의 사용 방법 Pending KR20260080518A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862727498P 2018-09-05 2018-09-05
US62/727,498 2018-09-05
US201862744073P 2018-10-10 2018-10-10
US62/744,073 2018-10-10
US201962815334P 2019-03-07 2019-03-07
US62/815,334 2019-03-07
US201962815880P 2019-03-08 2019-03-08
US62/815,880 2019-03-08
PCT/US2019/049816 WO2020051374A1 (en) 2018-09-05 2019-09-05 Allogeneic cell compositions and methods of use
KR1020217010008A KR102970392B1 (ko) 2018-09-05 2019-09-05 동종이계 세포 조성물 및 이의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010008A Division KR102970392B1 (ko) 2018-09-05 2019-09-05 동종이계 세포 조성물 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20260080518A true KR20260080518A (ko) 2026-06-02

Family

ID=68136519

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267016462A Pending KR20260080518A (ko) 2018-09-05 2019-09-05 동종이계 세포 조성물 및 이의 사용 방법
KR1020217010008A Active KR102970392B1 (ko) 2018-09-05 2019-09-05 동종이계 세포 조성물 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217010008A Active KR102970392B1 (ko) 2018-09-05 2019-09-05 동종이계 세포 조성물 및 이의 사용 방법

Country Status (8)

Country Link
US (1) US20220389077A1 (enExample)
EP (1) EP3847197A1 (enExample)
JP (2) JP7605735B2 (enExample)
KR (2) KR20260080518A (enExample)
CN (2) CN119119296A (enExample)
AU (1) AU2019335014B2 (enExample)
CA (1) CA3111384A1 (enExample)
WO (1) WO2020051374A1 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532987A (ja) * 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
US12173317B2 (en) 2018-03-28 2024-12-24 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector T cells
SG10201802979VA (en) * 2018-04-10 2019-11-28 Kah Meng Lim Immunological extract and method of production
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
EP3959305A1 (en) * 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
WO2021046261A1 (en) * 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
CN115315273A (zh) * 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
WO2021163191A1 (en) * 2020-02-10 2021-08-19 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
CN115515646A (zh) 2020-03-04 2022-12-23 波赛达治疗公司 用于治疗代谢性肝病的组合物和方法
US20230121433A1 (en) * 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
KR20210121585A (ko) * 2020-03-30 2021-10-08 한국세라믹기술원 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
EP4189072A4 (en) * 2020-07-29 2024-09-18 Eureka Therapeutics, Inc. T-CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
CN112375138B (zh) * 2020-11-13 2022-12-13 中元汇吉生物技术股份有限公司 一种重组载脂蛋白e和应用
CN112402592B (zh) * 2020-12-04 2023-06-02 中国人民解放军陆军军医大学 Spink7蛋白在制备促进过度炎症创面愈合的药物中的应用
CN112480242B (zh) * 2020-12-04 2023-06-06 中国人民解放军陆军军医大学 Spink7蛋白在制备预防和/或治疗溃疡性结肠炎的药物中的应用
EP4262840A4 (en) * 2020-12-18 2024-11-20 Cullinan Amber Corp. IMMUNOMODULATORY MOLECULES LOCALIZED IN BI-FUNCTIONAL LINEAR FUSION COLLAGEN AND THEIR METHODS
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
US20240139322A1 (en) * 2021-03-10 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
CN113249361A (zh) * 2021-03-29 2021-08-13 南京欧凯生物科技有限公司 基质金属蛋白酶及其制备方法
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
EP4082560B1 (en) * 2021-04-27 2025-02-26 Academia Sinica Prap1 polypeptide for use in treating hypertriglyceridemia
CN113481185B (zh) * 2021-08-05 2022-12-02 云南师范大学 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用
CN113846070B (zh) * 2021-10-18 2023-05-16 翌圣生物科技(上海)股份有限公司 高活性的mTET2酶突变体、其编码DNA及其应用
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
CN113957075B (zh) * 2021-11-22 2023-04-07 百世诺(北京)医学检验实验室有限公司 突变的遗传性心律失常基因及其应用
CN116178562A (zh) * 2021-11-29 2023-05-30 四川大学华西医院 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用
WO2023098729A1 (en) * 2021-11-30 2023-06-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
CN114539376B (zh) * 2022-01-17 2023-06-13 中国水产科学研究院南海水产研究所 拟穴青蟹生物标记物cyp2基因及其在制备病理检测试剂中的应用
CN114487448B (zh) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
CN114137231B (zh) * 2022-01-29 2022-04-29 北京大有天弘科技有限公司 一种血型不规则抗体的检测试剂盒及其应用
WO2023151620A1 (zh) * 2022-02-09 2023-08-17 恺兴生命科技(上海)有限公司 用于细胞免疫学的组合物和方法
CN114646764B (zh) * 2022-04-08 2024-11-29 华南农业大学 一种arhgap35蛋白在猪x和y精子鉴定或分离中的应用
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN114958862B (zh) * 2022-05-23 2023-12-08 郑州伊美诺生物技术有限公司 检测慢性间质性肾炎的重组抗原的制备方法
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
CN114989287B (zh) * 2022-06-06 2024-04-09 孙英贤 脱乙酰化修饰的baf155蛋白及其制药用途
CN114920816B (zh) * 2022-06-06 2024-04-05 孙英贤 Baf155突变基因及其制药用途
WO2024023245A1 (en) * 2022-07-27 2024-02-01 Biocell Innovations Pte. Ltd. Production of cells and viral vectors
CN115747170B (zh) * 2022-08-29 2023-08-04 四川大学 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用
CN115820580A (zh) * 2022-08-31 2023-03-21 武汉爱博泰克生物科技有限公司 活性重组hTET2蛋白的表达及纯化方法
CN115558712B (zh) * 2022-09-22 2026-03-24 华中科技大学同济医学院附属协和医院 Fam177a1的新用途
CN115850512B (zh) * 2022-10-14 2025-11-07 江苏大学 一种用于靶向治疗肿瘤的重组融合蛋白及其制备方法
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN115976004B (zh) * 2022-12-27 2024-07-09 天津科技大学 一种黄体酮17α-羟化酶突变体及其应用
EP4652153A1 (en) 2023-01-20 2025-11-26 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
GB2626983A (en) * 2023-02-10 2024-08-14 Quell Therapeutics Ltd Protein
CN116253778B (zh) * 2023-03-03 2025-09-23 中山大学 一种缓解长春新碱致神经病理性疼痛的多肽及其应用
CN118109416B (zh) * 2023-03-30 2024-11-22 广州百吉生物制药有限公司 功能增强型工程化免疫细胞及其制备和应用
KR20250173518A (ko) 2023-04-05 2025-12-10 포세이다 테라퓨틱스, 인크. 트랜스포사제 폴리뉴클레오티드 및 그의 용도
CN121195063A (zh) 2023-04-05 2025-12-23 波西达治疗公司 嵌合转座酶及其用途
WO2024211512A2 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Transposases and uses thereof
CN116478271B (zh) * 2023-06-19 2023-08-29 青岛大学 半滑舌鳎抗病基因PPARα及其编码蛋白的应用
CN119320771A (zh) * 2023-07-17 2025-01-17 北京艺妙神州医药科技有限公司 用于敲除t细胞中的trac和b2m的试剂和方法
CN116948015B (zh) * 2023-07-18 2024-07-05 山西锦波生物医药股份有限公司 生物合成人体结构性材料xxii型胶原蛋白的方法
WO2025029930A1 (en) * 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
CN116854801A (zh) * 2023-08-21 2023-10-10 广东省人民医院 Hand1重组蛋白及其制备方法和在治疗扩张性心肌病药物中的应用
CN122055354A (zh) 2023-09-01 2026-05-15 波西达治疗公司 类脂质化合物及相关组合物和用途
WO2025055927A1 (en) * 2023-09-13 2025-03-20 Qihan Hong Kong Limited Immunotherapies using hypoimmunogenic engineered cells
IL327036A (en) 2023-09-19 2026-05-01 Poseida Therapeutics Inc Compositions and methods for combining viral vectors
CN117586418B (zh) * 2023-11-08 2025-07-15 东南大学 一种丝氨酸蛋白酶抑制剂及其应用
WO2025106376A1 (en) * 2023-11-17 2025-05-22 Dna Twopointo Inc. Mammalian cell lines for transient protein production
CN117551621B (zh) * 2023-11-20 2024-04-30 梅州市人民医院(梅州市医学科学院) 一种杂交瘤细胞株l008、单克隆抗体及其应用
CN117883382B (zh) * 2023-11-27 2025-02-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途
CN117820434B (zh) * 2023-12-31 2024-11-19 武汉优恩生物科技有限公司 牛羊妊娠相关糖蛋白的多肽抗原及应用
WO2025156492A1 (zh) * 2024-01-23 2025-07-31 星尘股份有限公司 转座酶及其用途
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
CN118146342B (zh) * 2024-02-06 2026-06-26 同济大学 一种Smad5突变体及在防治糖尿病中的应用
CN117919389B (zh) * 2024-03-22 2024-07-23 上海南方模式生物科技股份有限公司 肿瘤新抗原dna疫苗
CN118584109B (zh) * 2024-03-26 2025-08-15 首都医科大学附属北京胸科医院 一种筛选耐药性肺癌的生物标志物
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
CN118308420B (zh) * 2024-04-19 2025-06-03 东北农业大学 一种大豆基因Glyma.18G041900的应用
CN118360271B (zh) * 2024-05-07 2025-12-05 中国海洋大学 一种脂肪酶突变体及其在提升白酒酯类风味物质中的应用
CN118240829B (zh) * 2024-05-21 2024-07-23 华南农业大学 NompC基因在防治桔小实蝇中的应用
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies
KR102974148B1 (ko) 2024-10-31 2026-06-10 한국생산기술연구원 신규한 경화제 및 경화제 제조방법
WO2026107088A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Dual car constructs and methods of use
WO2026107078A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Chimeric antigen receptor compositions and methods of use
CN119736407A (zh) * 2024-12-27 2025-04-01 西北农林科技大学 一种提高动物生长速度和大小的stc2基因编码序列突变体的应用
CN119899820B (zh) * 2025-01-23 2026-04-03 深圳开悦生命科技有限公司 Dhx8融合蛋白及其制备方法
CN120209114B (zh) * 2025-03-07 2026-04-07 首都医科大学 一种含有penk蛋白的组合物及其应用
CN119874865B (zh) * 2025-03-11 2025-11-25 东北林业大学 一种溪荪ost48蛋白在植物促分蘖中的应用
CN120192430B (zh) * 2025-03-24 2025-08-22 安康市中心医院 一种基于硒修饰的心肌保护多肽及其制备方法与应用
CN119978086B (zh) * 2025-03-31 2025-10-17 中国农业大学 一种调控植物生长发育的蛋白质dap1及其编码基因和应用
CN120607598B (zh) * 2025-05-16 2026-02-27 安徽大学 人源先锋转录因子sox15 hmg结构域重组蛋白及其制备方法
CN120624647B (zh) * 2025-05-30 2026-04-03 山西省肿瘤医院 鼻咽癌诊断或预测的甲基化标志物组合及应用、试剂盒和计算机可读存储介质
CN120591344B (zh) * 2025-06-13 2026-04-03 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用
CN120757661B (zh) * 2025-07-04 2026-05-26 江南大学 一种PTPσ_Ig1-3融合蛋白及其制备方法和应用
CN121203036B (zh) * 2025-09-24 2026-06-09 北京多美康医药科技有限公司 一种重组型胶原蛋白iii+x及其制备方法和应用
CN121186348B (zh) * 2025-11-25 2026-02-24 北京大学人民医院 瓜氨酸化内凝集素-1多肽在制备类风湿关节炎诊断产品中的应用
CN121471381B (zh) * 2026-01-12 2026-05-08 南京医科大学 Tat-po1及其在治疗神经退行性疾病肌萎缩侧索硬化症中的应用
CN121538143B (zh) * 2026-01-20 2026-04-10 北京绿色康成生物技术有限公司 生产麦角硫因的重组微生物、重组表达载体及制备麦角硫因的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
AU2015312117A1 (en) * 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
AU2017248830B2 (en) * 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US11725210B2 (en) * 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
JP2020530997A (ja) * 2017-08-08 2020-11-05 サンガモ セラピューティクス， インコーポレイテッド キメラ抗原受容体媒介性細胞標的化
BR112020018049A2 (pt) * 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso

Also Published As

Publication number Publication date
CA3111384A1 (en) 2020-03-12
WO2020051374A1 (en) 2020-03-12
KR20210073520A (ko) 2021-06-21
EP3847197A1 (en) 2021-07-14
US20220389077A1 (en) 2022-12-08
CN119119296A (zh) 2024-12-13
CN113383018B (zh) 2024-09-10
AU2019335014B2 (en) 2026-06-11
KR102970392B1 (ko) 2026-05-28
JP2021536249A (ja) 2021-12-27
JP2025028160A (ja) 2025-02-28
AU2019335014A1 (en) 2021-03-25
JP7605735B2 (ja) 2024-12-24
CN113383018A (zh) 2021-09-10
WO2020051374A9 (en) 2021-07-15

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201